Business Context and Reporting Period
Company: Precision Optics Corporation, Inc. (POCI)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended December 31, 2025
Business Overview: Developer and manufacturer of advanced optical instruments for medical devices and defense/aerospace markets. Operations include systems manufacturing, engineering design, Ross Optical components, and a MicroOptics Laboratory.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2025 |
|---|---|---|
| Revenue | $7,367,837 | $14,048,660 |
| Gross Profit | $204,660 | $1,151,018 |
| Gross Margin | 2.8% | 8.2% |
| Operating Loss | $(1,742,329) | $(3,337,584) |
| Net Loss | $(1,780,791) | $(3,417,821) |
| Loss Per Share (Basic/Diluted) | $(0.23) | $(0.44) |
| Cash and Equivalents (Dec 31, 2025) | $881,486 | |
| Total Debt (Current + Long-Term) | $1,587,421 | |
| Net Cash Used in Operating Activities (6mo) | $(177,852) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 62.8% for the quarter and 61.0% for the six months compared to the prior year periods. This was driven primarily by a 213.2% increase in Systems Manufacturing revenue.
- Margin Compression: Despite revenue growth, gross margins collapsed from 23.6% to 2.8% (quarter) and 25.1% to 8.2% (six months). Management attributed this to yield losses in single-use manufacturing lines, startup issues, and under-absorbed overhead.
- Segment Performance: Engineering Design Services revenue declined 31.2% (quarter) due to project completions and pipeline delays. MicroOptics Lab revenue dropped 60.1% due to defense customer order delays. Ross Optical Industries remained relatively flat with a 0.5% increase.
- Expense Trends: SG&A expenses increased 8.3% year-over-year for the six-month period, driven by stock-based compensation, executive severance, and consulting fees. R&D expenses decreased 21.9%.
- Liquidity Position: Cash balances decreased from $1.77 million to $0.88 million over the six-month period. Accounts payable increased significantly by $3.1 million.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt regarding the company's ability to continue as a going concern. Cash on hand ($0.9 million) is deemed insufficient to fund operations for the next 12 months without additional financing.
- Debt Covenants: The company is not in compliance with its minimum Debt Service Coverage ratio (1.20x) as of December 31, 2025. Future advances from the lender are contingent on achieving this ratio. A waiver was obtained for the fiscal year ending June 30, 2025, subject to an equity raise which was completed in February 2025.
- Strategic Actions: Management plans to improve yields, renegotiate pricing with customers (including tariff reimbursement), optimize headcount, and launch new development projects into manufacturing.
- Capital Needs: The company intends to seek additional funding through equity offerings, debt financing, or government funding. There is no assurance that such capital can be secured on favorable terms.
- Contractual Commitments: The company has approximately $7.07 million in open purchase orders and significant future lease obligations totaling over $3.8 million.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline and probability of securing the necessary equity or debt financing to address the "substantial doubt" regarding going concern status.
- Debt Covenant Compliance: Monitor the company's ability to meet the 1.20x Debt Service Coverage ratio to avoid default or further waivers on the Main Street Bank loan.
- Margin Recovery: Assess whether the yield losses in the single-use manufacturing line are temporary startup issues or indicative of structural production problems.
- Accounts Payable: Investigate the $3.1 million increase in accounts payable to determine if this represents a delay in payments to suppliers or a buildup of inventory costs.
- Customer Concentration: Review the dependency on specific defense customers given the significant revenue drop in the MicroOptics Lab segment due to order delays.